Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
Status:
Unknown status
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the
study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or
21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.